MultiGeneAngio is a cell therapy-based product proposed for use in patients with PAD secondary to blocked arteries in the legs. MultiGeneAngio is composed of a cell suspension of  endothelial and smooth muscle cells. The cells are isolated from a short vein segment stripped from the patient's arm under local anesthesia. After isolation, endothelial and smooth muscle cells are expanded, characterized, and finally gene modified by the transfer of angiogenic genes into these cells.
MultiGeneAngio is a clear cell suspension injected intra-arterially at the site of blockage using a standard diagnostic catheter, in order to expand and create new collateral arteries, thereby improving blood flow to the ischemic limb.

MGVS had completed enrollment and treatment of 12 patients with PAD at a stage of severe claudication as part of the first phase I/IIa study with MultiGeneAngio in two leading US medical centers. MGVS is currently preparing to conduct an additional phase I/IIa study of MGA, this time to treat critical limb ischemia in five leading Israeli medical centers. Critical limb ischemia is a severe stage of PAD, in which rest pain and non-healing ulcers appear and the patient is at risk of limb amputation.
For further details please see www.clinicaltrials.gov

| go to Products